518 related articles for article (PubMed ID: 27653912)
21. Therapeutic strategies for myasthenia gravis.
Keys PA; Blume RP
DICP; 1991 Oct; 25(10):1101-8. PubMed ID: 1803801
[TBL] [Abstract][Full Text] [Related]
22. Current trends in the management of myasthenia gravis: plasmapheresis and immunosuppressive therapy.
Pollard JD; Basten A; Hassall JE; Kronenberg H; Cobcroft R; Dawkins R
Aust N Z J Med; 1980 Apr; 10(2):212-7. PubMed ID: 6930213
[TBL] [Abstract][Full Text] [Related]
23. Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients.
Dau PC
Ann N Y Acad Sci; 1981; 377():700-8. PubMed ID: 6951494
[No Abstract] [Full Text] [Related]
24. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
[TBL] [Abstract][Full Text] [Related]
25. Update on immune-mediated therapies for myasthenia gravis.
Habib AA; Ahmadi Jazi G; Mozaffar T
Muscle Nerve; 2020 Nov; 62(5):579-592. PubMed ID: 32462710
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Myasthenia Gravis in the Aged.
Alkhawajah NM; Oger J
Drugs Aging; 2015 Sep; 32(9):689-97. PubMed ID: 26363907
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Myasthenia Gravis.
Farmakidis C; Pasnoor M; Dimachkie MM; Barohn RJ
Neurol Clin; 2018 May; 36(2):311-337. PubMed ID: 29655452
[TBL] [Abstract][Full Text] [Related]
28. Medical treatment options for ocular myasthenia gravis.
Antonio-Santos AA; Eggenberger ER
Curr Opin Ophthalmol; 2008 Nov; 19(6):468-78. PubMed ID: 18854691
[TBL] [Abstract][Full Text] [Related]
29. Steroids and immunosuppressant drugs in myasthenia gravis.
Sathasivam S
Nat Clin Pract Neurol; 2008 Jun; 4(6):317-27. PubMed ID: 18493241
[TBL] [Abstract][Full Text] [Related]
30. [Immunological and therapeutic aspects of myasthenia gravis (author's transl)].
Ghezzi M; Taiuti R; Marconi G
Riv Patol Nerv Ment; 1981; 102(1):12-28. PubMed ID: 6285444
[TBL] [Abstract][Full Text] [Related]
31. Myasthenia gravis. Pathogenesis and current concepts in management.
Havard CW; Scadding GK
Drugs; 1983 Aug; 26(2):174-84. PubMed ID: 6884241
[TBL] [Abstract][Full Text] [Related]
32. Myasthenia gravis: clinical, immunological, and therapeutic advances.
Romi F; Gilhus NE; Aarli JA
Acta Neurol Scand; 2005 Feb; 111(2):134-41. PubMed ID: 15644074
[TBL] [Abstract][Full Text] [Related]
33. Plasmapheresis therapy in myasthenia gravis.
Dau PC
Muscle Nerve; 1980; 3(6):468-82. PubMed ID: 7453714
[TBL] [Abstract][Full Text] [Related]
34. [Plasma exchange in myasthenia gravis].
Redeker M; Meyer-Wahl L
Nervenarzt; 1982 Dec; 53(12):729-32. PubMed ID: 7155236
[No Abstract] [Full Text] [Related]
35. Immunotherapy choice and maintenance for generalized myasthenia gravis in China.
Zhang C; Bu B; Yang H; Wang L; Liu W; Duan RS; Zhang M; Zeng P; Du C; Yang L; Shi FD
CNS Neurosci Ther; 2020 Dec; 26(12):1241-1254. PubMed ID: 33103369
[TBL] [Abstract][Full Text] [Related]
36. Case of severe refractory myasthenia gravis in HUKM.
Hamizah R; Norlinah MI; Tan HJ; Soehardy Z; Halim AG; Rohana AG; Hamidon BB; Kong NC; Raymond AA
Med J Malaysia; 2006 Dec; 61(5):633-5. PubMed ID: 17623968
[TBL] [Abstract][Full Text] [Related]
37. Management of myasthenia gravis.
Saperstein DS; Barohn RJ
Semin Neurol; 2004 Mar; 24(1):41-8. PubMed ID: 15229791
[TBL] [Abstract][Full Text] [Related]
38. Immunosuppressive treatment for juvenile myasthenia gravis.
Badurska B; Ryniewicz B; Strugalska H
Eur J Pediatr; 1992 Mar; 151(3):215-7. PubMed ID: 1601015
[TBL] [Abstract][Full Text] [Related]
39. [Immunosuppressive / immunomodulating therapies in myasthenia gravis-at present and in the near future].
Kawaguchi N
Brain Nerve; 2011 Jul; 63(7):737-43. PubMed ID: 21747144
[TBL] [Abstract][Full Text] [Related]
40. Myasthenia gravis: how to treat?
Tireli H; Karlikaya G; Tutkavul K; Akpinar A; Okay T
Acta Myol; 2004 Dec; 23(3):140-5. PubMed ID: 15938570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
